17 news items
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
AKRO
13 Jun 24
a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
AKRO
12 Jun 24
a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
AKRO
9 Jun 24
the opportunity to discuss your particular case. All communications will be treated in a confidential manner
Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
AKRO
8 Jun 24
forward to sharing our Week 96 data from the Phase 2b HARMONY study in patients with pre-cirrhotic MASH (F2–F3) with the scientific community at EASL
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
AKRO
7 Jun 24
the opportunity to discuss your particular case. All communications will be treated in a confidential manner
7o68p6x 8hcguj2fziqfuajqaypjqau5xwcvpnfsuv9n2rg
AKRO
6 Jun 24
or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated
lp7zohtjywcskzbjf1b1fp0rq710
AKRO
5 Jun 24
your particular case. All communications will be treated in a confidential manner
5b4xdj5 aomx
AKRO
3 Jun 24
the opportunity to discuss your particular case. All communications will be treated in a confidential manner
4iuy6f1wx35tywucau9srzkz0h0w843komm
AKRO
2 Jun 24
the opportunity to discuss your particular case. All communications will be treated in a confidential manner
yn89jlzz
AKRO
31 May 24
a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated
ziahqe 4ylh667ucn
AKRO
30 May 24
not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications
zu32ircabv7igt4kv54qeu8wghn35ugwcldub1
AKRO
24 May 24
or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated
edsqiji4was5essnmtb8pzicd4l4zmzeqqy371
AKRO
22 May 24
to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner
cbnid25q3blwankpn2b iwm6dmrykobk64uelfnd6d10k5ld0bnp0
AKRO
15 May 24
communications will be treated in a confidential manner
nikbjh xze5aks88wut
AKRO
8 May 24
not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications
8d8ua5k87874 0ysrkxbv8zwlatkzcp3prsjts89zjj5o7
AKRO
30 Apr 24
to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner
cm4j0k5dah265n w9n3z2iyqn67r7
AKRO
28 Mar 24
by attorneys in any of our offices. Johnson Fistel, LLP has paid for the dissemination of this promotional communication, and Frank J. Johnson
- Prev
- 1
- Next